NCT01317927View on ClinicalTrials.gov

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Solid TumorHematological Malignancy
Interventions
DRUG

Belinostat, Warfarin

1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO

Trial Locations (1)

84112

Huntsman Cancer Center, University of Utah, Salt Lake City

Sponsors

Collaborators (1)

Valerio Therapeutics
All Listed Sponsors
collaborator

Valerio Therapeutics

INDUSTRY

lead

Spectrum Pharmaceuticals, Inc

INDUSTRY

NCT01317927 - A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies | Biotech Hunter | Biotech Hunter